Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sapoval

Showing results (351-360 of 368) with videos related to

Pageof 37
Sort By:
Hypertension (Dallas, Tex. : 1979)|January 25, 2017
Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension)Philippe Gosse, Antoine Cremer, Helena Pereira, et al.
Circulation|September 1, 2016
Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) TrialMichel Azizi, Helena Pereira, Idir Hamdidouche, et al.
The Lancet Regional Health. Europe|July 7, 2023
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trialMarc Sapoval, Nicolas Thiounn, Aurélien Descazeaud, et al.
Journal of Human Hypertension|September 27, 2013
Blood pressure changes after renal denervation at 10 European expert centersA Persu, Y Jin, M Azizi, et al.
Journal of the American Heart Association|October 12, 2017
Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) TrialPierre-Yves Courand, Helena Pereira, Costantino Del Giudice, et al.
MMWR. Morbidity and Mortality Weekly Report|January 20, 2022
Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Community Wastewater - United States, November-December 2021Amy E Kirby, Rory M Welsh, Zachary A Marsh, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|December 5, 2006
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)L Norgren, W R Hiatt, J A Dormandy, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
Pageof 37

Showing results (351-360 of 368) with videos related to

Sort By:
Pageof 37
Hypertension (Dallas, Tex. : 1979)|January 25, 2017
Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension)Philippe Gosse, Antoine Cremer, Helena Pereira, et al.
Circulation|September 1, 2016
Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) TrialMichel Azizi, Helena Pereira, Idir Hamdidouche, et al.
The Lancet Regional Health. Europe|July 7, 2023
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trialMarc Sapoval, Nicolas Thiounn, Aurélien Descazeaud, et al.
Journal of Human Hypertension|September 27, 2013
Blood pressure changes after renal denervation at 10 European expert centersA Persu, Y Jin, M Azizi, et al.
Journal of the American Heart Association|October 12, 2017
Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) TrialPierre-Yves Courand, Helena Pereira, Costantino Del Giudice, et al.
MMWR. Morbidity and Mortality Weekly Report|January 20, 2022
Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Community Wastewater - United States, November-December 2021Amy E Kirby, Rory M Welsh, Zachary A Marsh, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|December 5, 2006
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)L Norgren, W R Hiatt, J A Dormandy, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
Pageof 37